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ABSTRACT
SKBR3-cells, characterized by ERBB2/RARA co-amplification, represent a 
subgroup of HER2+ breast-cancers sensitive to all-trans retinoic acid (ATRA) and 
Lapatinib. In this model, the two agents alone or in combination modulate the 
expression of 174 microRNAs (miRs). These miRs and predicted target-transcripts are 
organized in four interconnected modules (Module-1 to -4). Module-1 and Module-3 
consist of ATRA/Lapatinib up-regulated and potentially anti-oncogenic miRs, while 
Module-2 contains ATRA/Lapatinib down-regulated and potentially pro-oncogenic 
miRs. Consistent with this, the expression levels of Module-1/-3 and Module-2 
miRs are higher and lower, respectively, in normal mammary tissues relative to 
ductal-carcinoma-in-situ, invasive-ductal-carcinoma and metastases. This indicates 
associations between tumor-progression and the expression profiles of Module-1 to -3 
miRs. Similar associations are observed with tumor proliferation-scores, staging, size 
and overall-survival using TCGA (The Cancer Genome Atlas) data. Forced expression 
of Module-1 miRs, (miR-29a-3p; miR-874-3p) inhibit SKBR3-cell growth and Module-3 
miRs (miR-575; miR-1225-5p) reduce growth and motility. Module-2 miRs (miR-125a; 
miR-193; miR-210) increase SKBR3 cell growth, survival and motility. Some of these 
effects are of general significance, being replicated in other breast cancer cell lines 
representing the heterogeneity of this disease. Finally, our study demonstrates that 
HIPK2-kinase and the PLCXD1-phospholipase-C are novel targets of miR-193a-5p/
miR-210-3p and miR-575/miR-1225-5p, respectively.
INTRODUCTION
The estrogen receptor-negative and HER2+ SKBR3 
cell line is representative of a recently identified breast 
cancer subtype characterized by co-amplification of 
the genes coding for the HER2 membrane receptor 
(ERBB2) and the RARα nuclear retinoid receptor (RARA), 
respectively [1]. This breast cancer subtype is predicted to 
be extremely sensitive to the anti-tumor action of all-trans 
retinoic acid (ATRA), the active metabolite of vitamin 
A [1, 2]. In SKBR3 cells, simultaneous targeting of RARα 
with ATRA and HER2 with Lapatinib results in synergistic 
anti-tumor responses [1]. The molecular determinants at 
the basis of this anti-tumor activity need to be identified.
MicroRNAs (miRs) are short regulatory RNAs 
controlling the stability and translation of target 
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transcripts [3]. MiRs control numerous processes in the 
neoplastic cell [4, 5] and they can be characterized as 
oncogenic or anti-oncogenic [4–10]. The SKBR3 model 
provides a unique opportunity to establish whether 
miRs play any role in the cell-autonomous anti-tumor 
responses triggered by ATRA and Lapatinib. A potential 
role of these regulatory RNAs in the anti-tumor action 
of ATRA is suggested by studies performed in various 
cellular contexts [11–25], although very little information 
is available in the setting of breast cancer cells [26, 27]. 
In the estrogen receptor-positive MCF-7 cell line, 
ATRA causes up-regulation of a single miR, i.e. miR-21 
[27]. Similarly, there is limited experimental evidence 
on the links between miRs and Lapatinib anti-tumor 
activity [28–33].
Here, we demonstrate that ATRA and Lapatinib, 
alone or in combination, modify the miR expression 
profile of SKBR3 cells substantially. Some of the miRs 
up- or down-regulated by the two agents control the 
growth, survival and motility of SKBR3 cells and other 
cell lines representative of breast cancer heterogeneity. 
The regulated miRs and predicted target transcripts 
are organized in four highly interconnected functional 
modules. The miR expression fingerprints defined by the 
four modules are of general interest, being associated with 
breast cancer progression and prognosis.
RESULTS
Multiple anti-tumor responses in the SKBR3 
cell line by pharmacological targeting of 
HER2 and RARα
Targeting of HER2 with Lapatinib and RARα 
with ATRA results in a number of anti-tumor 
responses. Both ATRA and Lapatinib cause inhibition 
of SKBR3 cell growth, which is remarkably enhanced 
upon simultaneous exposure to the two compounds 
(Fig. 1A). In addition, a strong apoptotic response is 
evident upon co-treatment with ATRA and Lapatinib 
(ATRA+Lapatinib), as indicated by measurement of 
caspase-3/7 activity (Fig. 1B). This is observed in 
conditions where treatment with ATRA or Lapatinib 
alone does not result in apoptosis. Growth inhibition 
and programmed cell death are accompanied by signs 
of epithelial and lactogenic differentiation which are 
visible upon treatment with ATRA and to a greater extent 
by ATRA+Lapatinib [1]. Finally, challenge with the 
retinoid or the HER2 tyrosine kinase inhibitor decreases 
random-motility, a process associated with the invasive 
and metastatic behavior of cancer cells (Fig. 1C). Also 
in this case, co-treatment with ATRA and Lapatinib 
enhances the activity of the single components of the 
mixture. Altogether, our results indicate that ATRA and 
Lapatinib alone or in combination exert direct effects of 
therapeutic relevance on the neoplastic cell.
Perturbations of miR expression by ATRA  
and/or Lapatinib
To gain insights into the significance of miRs 
[20–25] for the responses triggered by the two anti-tumor 
compounds, we determined the expression profiles of these 
small regulatory RNAs in SKBR3 cells following challenge 
with vehicle, ATRA, Lapatinib and ATRA+Lapatinib for 
36 hours. Of the 1, 205 miRs represented on the microarray 
[27], 330 show detectable expression levels in at least one 
of the experimental conditions considered. One hundred 
and seventy four miRs are up- or down-regulated by ATRA, 
Lapatinib or ATRA+Lapatinib in a consistent and significant 
manner (Fig. 2A and Suppl. Table S1). Principal component 
analysis (PCA) of the data indicates that Lapatinib exerts a 
larger overall effect on the expression of these regulatory 
RNAs than ATRA (Fig. 2B). The combination of ATRA and 
Lapatinib results in a further quantitative and qualitative 
modulation of the miR expression profiles. The microarray 
data are validated and confirmed for 8 miRs by real-time 
quantitative PCR (qPCR) (Suppl. Fig. S1A). We took 
two representative miRs modulated predominantly by 
Lapatinib (miR-29a-3p) and by both ATRA and Lapatinib 
(miR-210-3p) for further time-course studies. The 
up-regulated miR-29a-3p, and the down-regulated 
miR-210-3p were selected based on the following 
criteria: a) high basal expression level; b) significant fold 
change caused by ATRA+Lapatinib; c) high correlation 
r2 value between the qPCR and the microarray data. 
Lapatinib causes an early induction of miR-29a-3p with 
a maximal effect at 20 hours, while miR-210-3p down-
regulation by ATRA and/or Lapatinib is gradual (Suppl. 
Fig. S1B).
Coordinated regulation of common target-
transcripts by multiple miRNAs
ATRA, Lapatinib and ATRA+Lapatinib cause 
significant perturbations of the miR and gene-expression 
profiles [1] (E-MEXP-3192; http://www.ebi.ac.uk/
arrayexpress) in SKBR3 cells (Suppl. Fig. S2). To 
identify potential miR targets from the 3, 144 mRNAs 
altered by the treatments applied and to study the 
organization of the predicted miR/target-transcript 
interactions, we used two independent criteria (MAGIA 
webtool, http://gencomp.bio.unipd.it/magia): 1) Direct 
target transcripts of the 174 miRs regulated by ATRA 
and/or Lapatinib must be predicted by at least one of 
the three algorithms considered; 2) Following treatment 
with ATRA, Lapatinib and ATRA+Lapatinib, the 
expression profiles of the candidate target mRNAs and 
the putative modulating miR(s) have to be inversely 
correlated (Spearman correlation index < −0.9). This 
results in 2, 829 possible miR/target-mRNA interactions 
involving 89 distinct miRs and 1, 116 mRNAs (Suppl. 
Table S2).
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Figure 1: Effect of ATRA and Lapatinib alone or in combination on the growth, apoptotic response and motility of 
SKBR3 cells. SKBR3 cells were treated with vehicle (DMSO), Lapatinib (100 nM), ATRA (100 nM) or Lapatinib+ATRA for the indicated 
amount of time. A. Time course for the growth inhibitory effects of ATRA and/or Lapatinib. Viable cells were counted following incubation 
with Trypan Blue. The results are the mean ± SD of 3 culture dishes. **Significantly different relative to vehicle treated cells (p < 0.01, 
Student’s t-test). B. Apoptotic response induced by ATRA and/or Lapatinib. The apoptotic response was evaluated by measuring the levels 
of caspase-3/7 activity on cell extracts obtained at the indicated time points using a fluorescent substrate. The results are the mean ± SD of 
3 culture dishes. **Significantly different relative to vehicle treated cells (p < 0.01, Student’s t-test). C. Effects of ATRA and/or Lapatinib on 
random cell motility. Random cell motility was evaluated by time-lapse microscopy. Each curve represents the motility of at least 40 cells. 
Each value is expressed as the mean ± SE of the distance migrated by each individual cell. **Significantly different (p < 0.01, two-way 
ANOVA Bonferroni post-test).
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Network analysis of these interactions reveals 
four highly interconnected miR and target-mRNA sub-
networks, which we define as Module-1 to Module-4 
(Fig. 2C and Suppl. Table S3). The four modules consist 
of miRs which are predicted to control the expression 
of multiple and common target-mRNAs (Fig. 3A-3D, 
lower schemes), a feature which is defined by the 
calculated degree of connectivity (Table 1). For each 
node (miR or target-mRNA) in the network, the degree of 
connectivity is the number of relations (edges) to the other 
Figure 2: Modulation of miR expression following treatment of SKBR3 cells with ATRA and/or Lapatinib and 
network analysis of the miR/target-mRNA interactions. SKBR3 cells were treated with vehicle (DMSO), Lapatinib (100 nM), 
ATRA (100 nM) or ATRA+Lapatinib for 36 hours. RNA was extracted and used for the determination of the miR expression profiles, 
using a miR microarray platform. A. Heat map of the miR expression profiles. The data are expressed as the Log2 of the miR expression 
ratio calculated for Lapatinib vs. vehicle (Lap), ATRA vs. vehicle (ATRA) and ATRA+Lapatinib vs. vehicle (A+L). Each result is the 
mean of 5 biological replicates. The miRs used for the validation and over-expression studies are indicated on the right. B. The Principal 
Component Analysis (PCA) of the miR expression levels observed in SKBR3 cells treated with ATRA, Lapatinib or the combination of the 
two compounds is shown. C. The panel illustrates the network representing the miR/target-mRNA interactions predicted by the MAGIA 
algorithm. The network consists of several modules and the four most inter-connected modules are indicated (Module-1 to -4). Cytoscape 
was used to build the network. The magenta nodes represent miRs, while the grey nodes represent miR target-mRNAs.
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Figure 3: Expression pattern and connectivity of the miRs and corresponding target-mRNAs in the four 
modules. The panels show the heat-maps of miR (upper-left) and miR target-mRNAs (upper-right) expression in SKBR3 cells challenged 
with ATRA, Lapatinib or ATRA+Lapatinib for 36 and 48 hours, respectively. The data are expressed as the Log2 of the miR expression ratio 
calculated for Lapatinib vs. vehicle (Lap), ATRA vs. vehicle (ATRA) and ATRA+Lapatinib vs. vehicle (A+L). A network representation 
(degree sorted circle layout) of the most connected miRs (magenta) and miR target-mRNAs (grey) is illustrated at the bottom of each panel. 
Panels A-D. illustrate the miRs and target-mRNAs belonging to Module-1 to -4, respectively. Each target-mRNA contained in the Network 
diagram of Module-1 and -3 are predicted to be regulated by at least 10 of the 17 miRs as well as at least 5 of the 13 miRs present in the two 
modules, respectively. Each target-mRNA contained in the Network diagram of Module-2 and -4 are predicted to be regulated by at least 
8 of the 12 miRs as well as at least 2 of the 5 miRs present in the two modules, respectively.
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nodes. For miRs, this is the number of predicted target-
mRNAs, while, for mRNAs, it is the number of miRs 
which are predicted to regulate their expression. Module-1 
is characterized by the largest number of miRs and the 
highest degree of connectivity, followed by Module-2, -3 
and -4 in sequence. Both Module-1 and -3 contain 
miRs and putative target-mRNAs which are up- and 
down-regulated, respectively, by the treatments applied. 
Module-2 is representative of miRs and target-mRNAs 
which are down-regulated and up-regulated, respectively, 
in our experimental conditions. The expression pattern of 
Module-4 miRs is more complex, as ATRA and Lapatinib 
alone have opposing effects on these regulatory RNAs. 
In Module-1, miR up-regulation and target-mRNA down-
regulation are predominantly afforded by Lapatinib and 
they are enhanced by ATRA+Lapatinib (Fig. 3A). In 
Module-2, ATRA is the predominant regulator of miRs 
and target-mRNAs (Fig. 3B). Module-3 consists of miRs 
up-regulated and mRNAs down-regulated predominantly 
by ATRA alone or in combination with Lapatinib 
(Fig. 3C). Module-4 contains miRs down-regulated by 
ATRA and up-regulated by Lapatinib as well as target-
transcripts with an opposite expression pattern (Fig. 3D).
Overall our data suggest that ATRA, Lapatinib and 
ATRA+Lapatinib regulate the expression of four groups 
of interconnected miRs, which, in turn, modulate gene-
product networks in a concerted manner.
Relative importance of Module-1 to -4 in 
the cellular processes associated with 
tumor progression
Enrichment analysis performed on the whole panel 
of miR target-genes contained in Module-1 to -4 (Suppl. 
Table S3) results in the identification of eleven process 
networks, which directly or indirectly control cell-cycle, 
apoptosis and cell motility/invasiveness in at least one of 
the modules (false discovery rate, FDR < 0.05, Table 2). 
Module-1 contains gene networks controlling mitosis and 
cell-cycle (G1- to S-phase progression) as well as blood 
vessel morphogenesis. Module-2 is involved in the growth 
factor regulation of G1- to S-phase transit and epithelial 
to mesenchymal transition (EMT), which is fundamental 
for cancer stem cell homeostasis and tumor cell motility/
invasiveness [34–37]. Module-3 is implicated in the 
WNT signaling pathway, which stimulates EMT [38–41]. 
In addition, the module is relevant for the process of 
apoptosis and contains the same networks of cell-cycle 
genes belonging to Module-1. Interestingly, the action 
of Module-1 and Module-3 miRs, which show similar 
regulation patterns, impinges on analogous processes. 
Module-4 is enriched in pathways related to cell motility/
invasiveness, such as cytoskeleton-rearrangement and 
cell-adhesion.
It remains to be established whether the enrichment 
of miR target-mRNAs involved in the control of key 
aspects of the cancer cell homeostasis, such as growth, 
survival, EMT and invasiveness mediates or is simply 
the consequence of the anti-tumor responses triggered by 
ATRA and/or Lapatinib in SKBR3 cells.
The miR fingerprints associated with the anti-
tumor action of ATRA+Lapatinib are related 
to breast cancer progression
Network and enrichment analyses indicate that miRs 
belonging to Module-1 through -4 act in a coordinated 
manner and control the expression of distinct target-
mRNA sets characterized by general relevance for the 
growth, survival and motile/invasive behavior of breast 
cancer cells. To evaluate whether the relevance of the miR 
fingerprints defined by the four modules goes beyond the 
specific cellular model used in our studies, we investigated 
the expression patterns of the miRs constituting Module-1 
to -4 in the clinical context of breast cancer.
In a first set of analyses, we evaluated the 
expression profiles of Module-1 to -4 miRs in a small and 
unique dataset (GSE38867) for which miR expression 
Table 1: MiR/mRNA composition and calculated degree of connectivity for the identified network




Whole Network 89 1, 118 2, 833 4.69 31.83 2.53
Module-1 17 332 1, 101 6.31 64.76 3.32
Module-2 12 276 805 5.59 67.08 2.92
Module-3 13 176 426 4.51 32.77 2.42
Module-4 5 94 124 2.51 24.80 1.32
No Module 42 240 377 2.67 8.98 1.57
The miRs and mRNAs modulated by ATRA and/or Lapatinib in SKBR3 cells were subjected to Network analysis which led 
to the identification of the four highly inter-connected modules (Module-1/Module-4). DOC = Degree of connectivity; No 
Module = miRs and mRNAs which fall outside Module-1 to Module-4.
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Total Module-1 Module-2 Module-3 Module-4
NOB NOB FDR NOB FDR NOB FDR NOB FDR
Cell cycle_
Mitosis 179 30 1.38E-15 2 0.962 9 0.020 3 0.418
Cell cycle_ 
G1-S











































159 8 0.272 6 0.283 8 0.027 1 0.783
All the miR target-mRNAs (Total) and the miR target-mRNAs present in Module-1 through Module-4 were analyzed 
for significant enrichment in the regulation of functional processes (Process Networks). The table shows enrichment 
analysis of the target genes in each Module on Metacore-annotated process networks (http://thomsonreuters.com/
metacore/). Each process represents a pre-set network of protein interactions defined and annotated in the Metacore 
platform. For each module and for all the process networks significantly enriched in 1 of the modules, the table reports the 
FDR (false discovery rate), the number and the list of object networks. The grey boxes indicate eleven process networks 
showing significant enrichment (FDR < 0.05) in at least 1 module. NOB = Network objects.
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data are available during different phases of disease 
progression (ductal carcinoma in-situ, DCIS; invasive 
ductal carcinoma, IDC; metastasis, MET) and in matched 
samples representing normal mammary tissue (NT). 
The heat-maps in DCIS, IDC and MET vs. NT (Fig. 4, 
left-panel) are highly suggestive of an inverse relationship 
between the expression profiles of miRs up- or 
down-regulated by ATRA and/or Lapatinib in SKBR3 
cells and the corresponding profiles observed in DCIS, 
IDC and MET. In other words, the levels of Module-1 
and -3 miRs up-regulated in response to the anti-cancer 
agents are generally lower in the three phases of tumor 
progression than in NT in six out of seven cases. Similarly, 
the expression of Module-2 and -4 miRs, which are 
predominantly down-regulated by the two drugs, tend 
to be higher in the three phases of tumor progression 
than in NT. This pattern is most evident when only the 
over-connected miRs (degree >50) are considered. To 
confirm this relationship in a quantitative manner, we 
defined similarity-scores based on all the miRs (General 
Score) or the subset of over-connected miRs (Impact 
Score). The General Score and the Impact Score were 
calculated for the whole signature (Whole) and for each 
module separately (Fig. 4, right-graphs). All the calculated 
scores show a general trend towards a decrease along 
disease progression. One-way ANOVA demonstrates 
significance in the case of the General Score determined 
for the whole signature. Interestingly, the greatest 
contribution to the observed decrease from NT to MET is 
provided by miRs belonging to Module-1 and Module-2.
The results obtained were validated and extended 
using the Cancer Genome Atlas (TCGA) dataset, which 
includes a cohort of 993 breast cancer cases. For 102 of 
these patients the miR expression profiles were determined 
Figure 4: Association of Module1-4 miR profiles with breast cancer progression. Using the GSE38867 from the NCBI Gene 
Expression Omnibus (http://www.ncbi.nlm.nih.gov/gds), the expression profiles of Module-1 to -4 miRs were determined at various stages 
of disease progression (NT = normal tissue; DCIS = ductal carcinoma in situ, IDC = invasive ductal carcinoma; MET = metastasis) 
in 7 breast cancer patients. Left: Heat-map of the miR expression values (Log2 ratios relative to the corresponding NT samples). The over-
connected miRs (miRs with degree >50, i.e. those with more than 50 predicted target-mRNAs) are indicated in square brackets. Right: 
The panels report two types of similarity scores: a General Score based on all the miRs and an Impact Score based on the subset of over-
connected miRs. Both score types were calculated using all 47 miRs (Whole) or the miRs contained in each module. Each point represents 
the mean ± SE of the score calculated in the 7 patients at the four stages. The indicated p-value is calculated by one-way ANOVA.
Oncotarget13184www.impactjournals.com/oncotarget
in tumors and matched normal mammary tissues. 
A significantly higher Impact Score value is observed 
in normal relative to tumor tissues in matched patients 
(Fig. 5A). This association is further supported in the 
remaining 891 tumors present in the database. Indeed, this 
set and the original group of 102 tumors are characterized 
by similar scores. The Impact Score value is also higher in 
normal relative to tumor-matched and tumor-unmatched 
samples, if only the miR fingerprint corresponding to 
Module-2 is considered. This is consistent with the 
idea that an effective anti-tumor treatment, such as the 
combination of ATRA and Lapatinib, modifies the miR 
profile of sensitive breast cancer cells to make it more 
similar to that observed in normal mammary cells. To 
support the relationship between our miR fingerprints 
and disease progression, we performed the same type of 
analysis after stratification of the tumors according to size, 
stage and cell-proliferation score. Tumors characterized 
by a small size (T1) show an Impact Score which is 
higher than the one observed in tumors characterized 
by progressively larger sizes (T2, T3 and T4) (Fig. 5B, 
upper-graphs). Once again a similar effect is evident if 
the analysis is restricted to the Module-2 Impact Score. 
Similarly, stage I show a higher Impact Score than stage 
II-IV tumors (Fig. 5B, lower-graphs). Finally, inverse 
correlations between Whole and Module-2 Impact Scores 
and the proliferation scores of each tumor sample are 
evident (Fig. 5C).
To evaluate whether the miR fingerprints identified 
by Module-1 to -3 have prognostic significance, we 
stratified the cases present in the TCGA dataset in 
quartiles according to their miR similarity scores. The 
cases in the upper quartile show an overall survival 
which is significantly more extended than the one 
observed in the lower quartile (Fig. 5D). The same type of 
analysis demonstrates that Module-2 is the only module 
characterized by a miR fingerprint associated with a better 
prognosis in terms of overall survival. The difference in 
survival maintains significance after multivariate COX 
proportional hazard analysis with size and stage.
Functional significance of selected Module-1 
and Module-3 miRs in SKBR3 cells
The Impact Scores calculated for Module-1 and 
Module-3 miRs reveal no significant associations with 
the tumor relative to the normal mammary gland tissue 
in the TCGA dataset. Although the integrated expression 
profiles of the most-interconnected miRs belonging to 
Module-1 and Module-3 are not associated with tumor 
progression, the finding does not rule out the possibility 
that single members of the two modules are endowed with 
anti-oncogenic properties and contribute to the anti-tumor 
activity of ATRA and/or Lapatinib. To address the point 
with a direct approach, we selected representative miRs 
from Module-1 (miR-29a-3p; miR-874-3p) and Module-3 
(miR-575; miR-1225-5p) and we performed functional 
studies following transient transfection of miR-mimics 
(Suppl. Fig. S3A).
The effect of mir-29a-3p, miR-874-3p, miR-575 and 
miR-1225-5p on cell growth and survival was evaluated 
following separate over-expression of the single miRs 
in exponentially growing SKBR3 cells (Fig. 6A). The 
action of the four miRs on the cell-cycle are consistent 
with a growth inhibitory response. Indeed, all the miRs 
increase the percentage of cells transiting through the 
G0/G1-phase at the expense of the S-phase. In the case 
of miR-874-3p and miR-575, a concomitant reduction 
in the G2/M-phase is observed. The growth inhibitory 
action of miR-29a-3p, miR-874-3p, miR-575 and miR-
1225-5p over-expression is not accompanied by apoptotic 
responses, as none of the miRs considered affects the 
basal levels of apoptosis-associated caspase-3/7 enzymatic 
activity (data not shown). The proposed anti-proliferative 
action of the selected Module-1 and Module-3 miRs is 
consistent with the predicted anti-oncogenic properties. In 
addition, induction of these miRs is likely to contribute to 
the anti-proliferative responses triggered by ATRA and/or 
Lapatinib in SKBR3 cells.
The General and/or Impact Scores calculated in the 
small GSE38867 breast cancer dataset indicate the miR 
expression profiles of Module-1 and, to a lesser extent, 
Module-3 show a higher degree of similarity in NT than in 
DCIS, IDC or MET. The finding suggests a possible role 
of these miRs in regulating the invasive and metastatic 
behavior of breast cancer cells which is suppressed by 
ATRA and/or Lapatinib (see Fig. 1C). Thus, miR-29a-3p, 
miR-874-3p, miR-575 and miR-1225-5p were tested for 
their action on SKBR3 cell random-motility by time-lapse 
microscopy (Fig. 6B). With regards to Module-1, over-
expression of miR-874-3p does not alter cell motility, while 
over-expression of miR-29a-3p increases cell-migration. 
This last finding is consistent with a positive action on 
EMT [42], a major determinant of cell motility. In contrast, 
over-expression of Module-3 miR-575 and miR-1225-5p 
inhibits SKBR3 random motility. Our results indicate that 
miR-575 and miR-1225-5p up-regulation contributes to the 
anti-motility action of ATRA and/or Lapatinib. By converse, 
up-regulation of miR-29a-3p plays a detrimental role in the 
process. The data support the involvement of Module-1 and 
Module-3 miRs in breast cancer invasiveness.
The effects on two important processes associated 
with tumor progression are consistent with the idea that the 
tested miRs are endowed with anti-oncogenic properties.
Functional validation studies with representative 
Module-2 miRs in SKBR3 cells
We performed functional validation studies with 
selected Module-2 miRs. The experiments were aimed at 
testing the oncogenic properties of Module-2 miRs and 
the role played by their down-regulation in the anti-tumor 
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Figure 5: Association of Module-1 to -4  miR  profiles  with  clinical  indicators  in  the  breast  cancer  TCGA 
dataset. A. The Impact Score for the Whole (left) and Module-2 (right) miR signatures was calculated for 102 normal mammary tissue 
samples and matched breast cancer samples as well as 891 unmatched tumors present in the TCGA dataset. The values are the mean ± SE 
of the indicated number of patients. The p-values refer to paired t-tests. B. The panel reports the same scores as in A after stratification of 
the tumor samples for size (T1-T4, upper graphs) and stage (I-IV, lower graphs). The values are the mean ± SE of the indicated number of 
patients. The p-values refer to Tukey’s tests following one-way ANOVA. C. The Impact Score for the Whole (left) and Module-2 (right) miR 
signatures were plotted against the PAM50 proliferation score. The r Pearson correlation values and the statistical significance are indicated. 
D. Kaplan-Meier overall survival curves for patients falling within the upper (dotted line, UQ) and lower (solid line, LQ) quartiles of the 
Whole and Module-2 scores. The indicated p-values refer to the log-rank test. The values after correction for tumor size and stage with Cox 
proportional hazard test are shown in parenthesis.
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Figure 6: Over-expression of selected Module-1 and Module-3 miRs up-regulated by ATRA and/or Lapatinib: effects 
on SKBR3 cell-cycle and motility. SKBR3 cells were co-transfected with the indicated miRs (30 nM) or an appropriate control miR 
(Neg) and the pEGFP-N1 plasmid (0.01 nM) allowing expression of the GFP protein. A. Forty eight hours following transfection, cells were 
collected, fixed and stained with propidium iodide before subjecting them to FACS analysis. The bar graphs show the percentage of GFP-
positive cells transiting through the indicated phase of the cell-cycle. Each value is the mean ± SD of three replicate cultures. *Significantly 
different (p < 0.05, Student’s t-test). **Significantly different (p < 0.01, Student’s t-test). B. Forty eight hours after transfection with the 
indicated miRs, SKBR3 cells were seeded in 24-well plates and random cell motility of GFP-positive cells was evaluated by time-lapse 
microscopy. Each value is the mean ± SE of at least 38 individual cells. *Significantly different (p < 0.05, two-way ANOVA Bonferroni 
post-test). **Significantly different (p < 0.01, two-way ANOVA Bonferroni post-test).
action of ATRA and/or Lapatinib. For these studies, we selected 
miR-125a-5p, miR-193a-5p as well as miR-210-3p and we 
evaluated the effects of miR over-expression (Suppl. Fig. S3B) 
on the growth, apoptosis and motility of SKBR3 cells.
The significance of the selected miRs for the growth-
inhibitory process was established in basal conditions, and 
following treatment with ATRA and Lapatinib alone or in 
combination (Fig. 7A). Forced expression of miR-125a-5p 
and miR-193a-5p increases the basal growth of SKBR3 cells. 
A similar trend is observed following 48 hours of treatment 
with a sub-optimal concentration of ATRA, which causes no 
significant growth-inhibition in our experimental conditions. 
MiR-125a-5p and miR-193a-5p partially reverse the anti-
proliferative effects of Lapatinib, while all the miRs considered, 
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including miR-210-3p, contrast growth-inhibition by 
ATRA+Lapatinib. Thus, down-regulation of these Module-2 
miRs by ATRA and/or Lapatinib may contribute to the 
observed anti-proliferative/cyto-toxic activity. In the case 
of miR-193a-5p and miR-210-3p, growth stimulation is 
probably the result of cell-cycle regulation, as these miRs 
decrease the number of cells transiting through the G0/G1-
phase and increase the S and G2/M phase cell population 
(Fig. 7B). Interestingly, the modulatory effects on the cell-
cycle are enhanced when cells are transfected with a mixture 
of the three miRs, suggesting a coordinated action. The 
effects of the three selected miRs extend to cell survival. 
Indeed, miR-125a-5p, miR-193a-5p and miR-210-3p 
over-expression diminishes caspase-3/7 activity, indicating 
an anti-apoptotic effect (Fig. 7C). SKBR3 cell-survival is 
not further augmented by combined transfection of the three 
miRs, suggesting common underlying mechanisms. This 
supports the idea that down-regulation of miR-125a-5p, 
miR-193a-5p and miR-210-3p contributes not only to the 
growth-inhibitory, but also to the cyto-toxic activity of 
ATRA and/or Lapatinib. Individual transfection of miR-
125a-5p, miR-193a-5p or miR-210-3p does not alter SKBR3 
cell motility. However, combined transfection of the three 
miRs significantly stimulates this process (Fig. 7D). Thus, 
coordinated down-regulation of these miRs may contribute 
to the anti-motility action of ATRA and/or Lapatinib.
Figure 7: Over-expression of selected Module-2 miRs down-regulated by ATRA and/or Lapatinib: effects on SKBR3 
growth, cell-cycle, apoptosis and motility. A. SKBR3 cells were transfected with the indicated miRs or an appropriate control miR 
(Neg). Twenty four hours following transfection, cells were challenged with vehicle (DMSO), ATRA (100 nM), Lapatinib (Lap, 100 nM) or the 
combination of the two compounds for a further 48 hours. Cells were subject to an MTT assay for the quantitative determination of cell growth. 
Each value is the mean ± SD of 5 separate cultures. *Significantly different (p < 0.05, Student’s t-test). **Significantly different (p < 0.01, 
Student’s t-test). B. Logarithmically growing SKBR3 cells were co-transfected with the indicated miRs (30 nM) alone or in combination 
(10 nM each; mix) and the pEGFP-N1 plasmid (0.01 nM) allowing expression of the GFP protein. The bar graphs show the percentage of GFP-
positive cells transiting through the indicated phase of the cell-cycle. Each value is the mean ± SD of three replicate cultures. *Significantly 
different (p < 0.05, Student’s t-test). **Significantly different (p < 0.01, Student’s t-test). C. SKBR3 cells were transfected with the indicated 
three miRs alone or in combination (10 nM each; mix) and the negative control miR (Neg). Forty eight hours after transfection, cells were lysed 
and caspase 3/7 enzymatic activity was determined. The values represent the mean + SD of three replicate cultures. *Significantly different 
(p < 0.05, Student’s t-test). **Significantly different (p < 0.01, Student’s t-test). D. Forty eight hours after transfection with the indicated 3 miRs 
alone or in combination (10 nM each; mix) and the negative control miR (Neg) in the presence of pEGFP-N1 as in (B), SKBR3 cells were 
seeded in 24-well plates and random cell motility of individual GFP-positive cells was evaluated by time-lapse microscopy. Each value is the 
mean ± SE of at least 27 individual cells. **Significantly different (p < 0.01, two-way ANOVA Bonferroni post-test).
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Expression profiles and functional effects of 
Module-2 miRs in other breast cancer cell lines
We evaluated whether the anti-oncogenic properties 
of Module-2 miRs extend beyond the specific model of the 
SKBR3 cells. To this purpose, we performed expression 
and functional studies in four cell lines representative 
of breast cancer heterogeneity. The panel consists of 
two luminal cell types characterized by ER-positivity 
(MCF-7) and ERBB2 amplification (MDA-MB-453), as 
well as two Basal/TN cell types (MDA-MB231 and MDA-
MB157). The four cell lines show variable sensitivity to 
ATRA and Lapatinib (Suppl. Table S4).
In a first set of experiments, we determined the action 
of ATRA and Lapatinib on the levels of miR-125a-5p, 
miR-193a-5p and miR-210-3p, in the four cell lines and 
SKBR3 as a control. Similar to what is observed in the 
SKBR3 model, ATRA down-regulates all the Module-2 
miRs considered in Luminal/ER+ MCF-7 cells (Fig. 8A). 
Significant ATRA-dependent down-regulation is observed 
for miR-125a-5p and miR-210-3p in the other retinoid-
sensitive MDA-MB-157 cell line. In contrast, none of the 
miRs is regulated by ATRA in retinoid refractory MDA-
MB-231 and MDA-MB-453 cells. The results suggest that 
down-regulation of miR-125a-5p, miR-210-3p and possibly 
miR-193a-5p is associated with the anti-proliferative action 
of ATRA. As for Lapatinib, the kinase inhibitor down-
regulates miR-193a-5p in the Her2+ MDA-MB-453 cell 
line. At variance with SKBR3 cells, Lapatinib does not alter 
the expression of miR-125a-5p or miR-210-3p in MDA-
MB-453 cells. None of the Module-2 miRs is regulated 
by the tyrosine kinase inhibitor in Her2- and Lapatinib-
refractory MCF-7, MDA-MB157 and MDA-MB231.
We further investigated whether down-regulation 
of Module-2 miRs by ATRA and/or Lapatinib is a 
consequence of cell growth inhibition or cytotoxicity and it 
is independent of the anti-tumor agent considered. To this 
purpose, we evaluated the expression of miR-125a-5p, 
miR-193a-5p and miR-210-3p following treatment with 
doxorubicin (Doxo), an anti-tumor agent inhibiting the 
growth of all our cell lines in the concentration range 
considered (Fig. 8B). At concentrations reducing cell 
numbers by approximately 25% in 24 hours (Suppl. 
Table S4), miR-125-5p is significantly down-regulated by 
Doxo in MDA-MB-157, MDA-MB-231, MDA-MB453 and 
SKBR3 cells. Doxo causes a significant down-regulation 
of miR-193a-5p in MDA-MB231 and SKBR3 cells. Except 
for MDA-MB157, Doxo reduces the expression of miR-
210-3p in all the cell lines tested. Taken together, the 
data obtained support the idea that down-regulation of 
Module-2 miRs is a general response of all breast cancer 
cell lines to growth inhibitory or cyto-toxic stimuli.
In a series of functional studies, we evaluated 
whether the growth stimulatory, anti-apoptotic and pro-
motility actions of Module-2 miR-125a-5p, miR-193a-5p 
and miR-210-3p are limited to SKBR3 or they extend to 
the other breast cancer cell lines considered. The effects on 
cell growth were determined by measuring perturbations 
in the cell-cycle following over-expression of the three 
Module-2 miRs alone or in combination. Over-expression 
of the three miRs in all the cell lines following transfection 
was confirmed by qPCR (data not shown). In MDA-
MB157 cells, forced expression of miR-125a-5p and miR-
210-3p replicates the proliferative effect established in 
the SKBR3 counterparts. In fact, the two miRs contract 
the G0/G1 phase and expand the S-phase of the cell cycle 
(Fig. 9A). The growth stimulatory action is maintained, 
if the three miRs are simultaneously transfected, which 
is suggestive of cooperative effects. Similar pro-growth 
responses are observed following individual transfection 
of miR-193a-5p and miR-210-3p in MDA-MB231 cells. 
In the MDA-MB453 line, forced expression of miR 
125a-5p and miR210-3p reduces the fraction of cells 
transiting through the G0/G1 phase, once again consistent 
with a proliferative action. Noticeably, individual and 
combined over-expression of miR-125a-5p, miR-193a-5p 
and miR-210-3p in the Luminal/ER+ MCF-7 cell line 
exerts opposite actions which are consistent with an 
overall growth inhibitory effect. Indeed, individual 
over-expression of the three Module-2 miRs in MCF-7  
cells results in a consistent expansion of the G0/G1 
phase and/or a reduction of the S phase. These effects 
are accompanied by variable perturbations of the G2/M 
phase. Interestingly, the anti-proliferative action of miR-
125a-5p in MCF-7 cells confirms results obtained in the 
same cellular context by Guo et al. [43]. Taken together 
these studies indicate that the action of Module-2 miRs on 
the cell-cycle is highly dependent on the cellular context 
considered. Nevertheless, with the exception of MCF-7, 
the three Module-2 miRs exert a predominant growth-
stimulatory effect in breast cancer cells.
As far as apoptosis is concerned, individual over-
expression of miR-125a-5p, miR-193a-5p and miR-210-3p 
does not exert any significant effect on caspase-3/7 
activation in MCF-7, a known caspase-3 defective cell 
line [43], MDA-MB157, MDA-MB231 and MDA-MB-453 
cells (Fig. 9B). This is different from what is observed in 
SKBR3 cells, where these miRs are characterized by an 
anti-apoptotic action (see Fig. 7C). However, combined 
transfection of the three miRs in MCF-7 and MDA-MB231 
cells causes a significant inhibition of caspase-3/7 activity. 
The data support the idea that the coordinated action of 
Module-2 miRs triggers not only a growth inhibitory, but 
also an anti-apoptotic effect in specific cellular contexts.
The effect exerted by miR-125a-5p, miR-193a-5p 
and miR-210-3p on the migratory behavior of breast 
cancer cells was investigated. Similar to what is 
observed in SKBR3, only combined transfection of the 
three Module-2 miRs results in increased migration 
of the Basal/TN and highly motile MDA-MB157 cells 
(Fig. 10). In the other Basal/TN MDA-MB-231 cell 
line, transfection of miR-210-3p significantly increases 
Oncotarget13189www.impactjournals.com/oncotarget
random-motility, although a similar effect seems to 
occur also in the case of miR-125a-5p. In MDA-MB-231 
cells, combined transfection of the three Module-2 
miRs is no more effective than miR-210-3p. In the 
Luminal MCF-7 and MDA-MB-453 cell lines, which 
are characterized by much lower motility than the 
two Basal/TN counterparts, the picture is complex. 
In MCF-7 cells, motility is increased by miR-125a-5p, 
it is decreased by miR-193a-5p and it is left unaffected 
by miR-210-3p. In MDA-MB-453 cells, the only miR 
exerting an effect is miR-193a-5p, which reduces 
motility. Thus, the Luminal and Basal/TN phenotypes 
seem to represent primary determinants of the motility 
responses triggered by the Module-2 miRs considered.
Figure 8: Expression of selected Module-2 miRs in breast cancer cell lines challenged with ATRA, Lapatinib and 
Doxorubicin. A. The indicated cell lines were treated with vehicle (DMSO), ATRA (MCF-7 = 1 μM; MDA-MB157 = 1 μM; MDA-
MB231 = 1 μM; MDA-MB453 = 1 μM; SKBR3 = 0.1 μM) or Lapatinib (MCF-7 = 0.1 μM; MDA-MB157 = 0.1 μM; MDA-MB231 = 0.1 μM; 
MDA-MB453 = 1 μM; SKBR3 = 0.1 μM) for 30 hours. The graphs illustrate the expression profiles of the indicated Module-2 miRs, as 
determined by quantitative real-time PCR (qPCR). Each qPCR value is the mean of 3 replicates ± SD. B. The indicated cell lines were 
treated with vehicle (DMSO) or Doxorubicin (MCF-7 = 0.25 μM; MDA-MB157 = 0.1 μM; MDA-MB231 = 0.1 μM; MDA-MB453 = 0.5 μM; 
SKBR3 = 0.1 μM) for 24 hours. The results were obtained by qPCR analysis as in A. Each result is the mean of 3 replicates ± SD. **Significantly 
different (p < 0.01, Student’s t-test). *Significantly different (p < 0.05, Student’s t-test). Lap = Lapatinib; Doxo = Doxorubicin.
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Two novel targets of Module-2 and Module-3 
miRs: HIPK2 and PLCXD1
We functionally validated if any of the predicted 
target-genes contained in the identified modules are 
indeed regulated by the corresponding miRs. For these 
experiments, we selected one gene from Module-2 (HIPK2, 
homeodomain-interacting-protein-kinase-2) and another 
gene from Module-3 (PLCXD1, phosphatidylinositol-
specific phospholipase-C-X-domain-containing-1), 
representing potential targets of miRs which are regulated 
in SKBR3 cells treated with ATRA and/or Lapatinib. In the 
case of both HIPK2 and PLCXD1, selection was dictated 
by high basal expression levels and robust fold-change 
Figure 9: Over-expression of selected Module-2 miRs; effects on cell-cycle and apoptosis in breast cancer cell 
lines. A. The listed cell lines were co-transfected with the indicated miRs (30 nM) alone or in combination (10 nM each; mix) and the 
pEGFP-N1 plasmid (0.01 nM) allowing expression of the GFP protein. The bar graphs show the percentage of GFP-positive cells transiting 
through the indicated phase of the cell-cycle. Each value is the mean ± SD of 3 replicate cultures. *Significantly different (p < 0.05, 
Student’s t-test). **Significantly different (p < 0.01, Student’s t-test). B. The indicated cell lines were transfected with miR-125a-5p, 
miR-193a-5p and miR-210-3p and the negative control miR (Neg). Forty eight hours after transfection, cells were lysed and caspase 3/7 
enzymatic activity was determined. The values represent the mean ± SD of three replicate cultures. *Significantly different (p < 0.05, 
Student’s t-test). **Significantly different (p < 0.01, Student’s t-test).
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upon treatment with ATRA and/or Lapatinib. HIPK2 
is one of the most inter-connected targets of Module-2 
miRs and it is considered to be an onco-suppressor, as it 
is a pro-apoptotic agent and it inhibits the invasiveness of 
breast cancer cells [44–46]. The function of PLCXD1 is 
largely unknown although its over-expression suppresses 
melanoma cell growth, suggesting anti-oncogenic 
properties [47].
In SKBR3 cells, the HIPK2 mRNA is rapidly 
up-regulated by ATRA (Fig. 11A). Up-regulation 
is observed also with Lapatinib, although the effect is 
more delayed. The increase in HIPK2 mRNA is higher 
in cells exposed to ATRA+Lapatinib relative to ATRA 
alone. Over-expression of miR-193a-5p or miR-210-3p 
(Module-2) in SKBR3 cells down-regulates the HIPK2 
transcript (Fig. 11B). In contrast, transfection of miR-
125a-5p has no significant effect on the steady-state levels 
of the mRNA. Down-regulation of the HIPK2 mRNA 
by miR-193a-5p and miR-210-3p translates into down-
regulation of the corresponding protein. Thus, HIPK2 is 
a novel and common target of miR-193a-5p and miR-
210-3p. In SKBR3 cells, down-regulation of the two miRs 
by ATRA and ATRA+Lapatinib is likely to contribute to 
HIPK2 up-regulation by the two stimuli.
Figure 10: Over-expression of selected Module-2 miRs; effects on the motility breast cancer cell lines. The indicated cell 
lines were transfected with the indicated miRs alone (30 nM) or in combination (10 nM each; mix) and the negative control miR (Neg) in 
the presence of pEGFP-N1 (0.01 nM). Forty eight hours after transfection, cells were seeded in 24-well plates and random cell motility 
of individual GFP-positive cells was evaluated by time-lapse microscopy. Each value is the mean ± SE of at least 27 individual cells. 
*Significantly different (p < 0.05, two-way ANOVA Bonferroni post-test) **Significantly different (p < 0.01, two-way ANOVA Bonferroni 
post-test).
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The PLCXD1 transcript is down-regulated by ATRA 
and Lapatinib at both 12 and 48 hours. Down-regulation 
is enhanced by the combination of ATRA+Lapatinib at the 
two time points considered (Fig. 11A). Forced expression 
of miR-575 and miR-1225-5p (Module-3) decreases the 
levels of the PLCXD1 mRNA, although the effect reaches 
Figure 11: Regulation of HIPK2 and PLCXD1, two novel targets of specific miRs up- and down-regulated by ATRA 
and/or Lapatinib. A. The expression pattern of HIPK2 and PLCXD1 transcripts in SKBR3 cells challenged with ATRA (100 nM), 
Lapatinib (100 nM) and the combination of the two compounds for 12 and 48 hours is illustrated. The results were obtained from the gene-
expression microarray experiments. Each value is expressed in fold-change relative to the vehicle treated control and it is the mean ± SD 
of 5 replicate arrays. **Significantly different (p < 0.01, Student’s t-test). B. SKBR3 cells were transfected with the indicated miRs and an 
appropriate control miR (Neg). After 48 hours, total RNA was extracted and the levels of HIPK2 and PLCXD1 mRNAs were determined 
with the use of specific Taqman assays (upper graphs). **Significantly different (p < 0.01, Student’s t-test). In the same experimental 
conditions, the levels of HIPK2 and PLCXD1 proteins were determined by Western blot analysis (bottom images). The filters used for 
Western blot analyses were re-blotted with an anti-β-actin antibody, which demonstrates that the same amount of protein was loaded in each 
lane. Densitometric quantification of the HIPK2 and PLCXD1 bands is shown by the middle bar graphs.
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statistical significance only in the case of miR-1225-5p 
(Fig. 11B). The two miRs also cause a reproducible 
and robust reduction in the amounts of the PLCXD1 
protein. Thus, the regulatory effect exerted by miR-575 
is predominantly due to inhibition of protein synthesis, 
while miR-1225-5p affects both RNA stability and 
translation efficiency. A third miR belonging to Module-3, 
i.e. miR-188-5p, does not alter the levels of either the 
PLCXD1 mRNA or protein. The data indicate that 
PLCDX1 is a novel and common target of miR-575 and 
miR-1225-5p. In addition, they support the idea that 
up-regulation of the two miRs by ATRA, Lapatinib and 
ATRA+Lapatinib contributes to the down-regulation of 
PLCXD1 in SKBR3 cells.
DISCUSSION
SKBR3 cells are characterized by co-amplification 
of the genes coding for HER2 and the nuclear retinoic 
acid receptor, RARα, and they are representative of a 
novel subgroup of HER2+ breast tumors with selective 
sensitivity to simultaneous targeting of RARα with ATRA 
and HER2 with Lapatinib [1]. In this study, the SKBR3 
breast cancer model is used to demonstrate that ATRA and 
Lapatinib regulate 174 miRs and predicted target-mRNAs 
which modulate proliferation, survival and invasiveness, 
contributing to the anti-tumor action of the two 
compounds. About one quarter of ATRA and/or Lapatinib 
regulated miRs (47/174) and potential target-mRNAs are 
organized in four highly interconnected modules.
Module-1 consists of miRs whose expression is 
increased by Lapatinib and enhanced by ATRA+Lapatinib. 
In Module-1, up-regulation of miR-26a, mir-29a-3p, miR-
30d, miR-134, miR-181a, miR-320c, miR-874-3p, miR-
1226, miR-1181 and miR-1915 by Lapatinib and/or ATRA 
is entirely consistent with the generally accepted anti-
oncogenic action of these miRs in breast cancer or other 
tumors (Suppl. Table S5). In fact, miR-26a is reported to 
inhibit the growth and motility of breast cancer cells [48]. 
The expression profile of miR-134 in the same tumor 
type suggests that the miR is an onco-suppressor [49]. 
Interestingly, miR-134 targets HER2 [50], whose gene is 
amplified and active in SKBR3 cells [1]. MiR-181a is also 
likely to be an onco-suppressor, as it reduces the ability 
of breast cancer cells to induce mammospheres [51]. The 
only two miRs whose up-regulation by Lapatinib and 
ATRA+Lapatinib is against the predicted anti-oncogenic 
action are miR-150, which promotes the growth of certain 
mammary carcinoma cells [52], and miR-762, which is 
up-regulated in oral squamous carcinomas [53]. With 
the use of an over-expression approach, two of the miRs 
belonging to Module-1, i.e. mir-29a-3p and miR-874-3p, 
were directly evaluated for their action on SKBR3 cell 
survival, growth and motility. Forced expression of 
neither mir-29a-3p nor miR-874-3p affects the process of 
apoptosis, indicating that the two miRs are not involved 
in the regulation of SKBR3 cell survival. In contrast, 
mir-29a-3p and miR-874-3p play a role in the process of 
cell proliferation. In particular, the anti-proliferative effect 
of mir-29a-3p recapitulates what was observed in two 
other breast cancer cell lines [54], while growth inhibition 
by miR-874-3p is consistent with its tumor-suppressor role 
in non-small-cell lung as well as head and neck cancers 
[55–57]. As for this last miR, it would be interesting to 
know whether miR-874-3p exerts the same suppression of 
the cancer stem-cell phenotype described in lung cancer 
also in mammary tumors. Unlike miR-874-3p, miR-29a-3p 
over-expression exerts a significant stimulatory effect on 
SKBR3 cell motility. This last observation is unexpected, 
as the miR has been reported to down-regulate Sparc, a 
protein stimulating breast cancer cell invasiveness [58].
In Module-2, miR down-regulation is predominantly 
due to ATRA and ATRA+Lapatinib. Down-regulation of 
miR-96, miR-203 and miR-210-3p is consistent with 
the predicted oncogenic properties of the three miRs 
[59–64]. Noticeably, miR-96 promotes breast cancer cell 
proliferation targeting FOXO3A, which is a major node of 
ATRA/Lapatinib cross-talk in SKBR3 cells [1]. MiR-203 is 
under-expressed in invasive relative to non-invasive breast 
cancer cells [65], although the miR seems to function as 
a tumor-suppressor in triple-negative carcinomas [66]. 
In contrast, down-regulation of miR-15b, miR-149 
and miR-183 is hard to reconcile with their predicted 
anti-oncogenic potential [67–70]. With the same over-
expression approach used for Module-1, we evaluated 
the action of miR-125a-5p, miR-193a-5p and miR-210-
3p on the proliferation, survival and motility of SKBR3 
cells. The results indicate that individual down-regulation 
of the three miRs contributes to the anti-proliferative 
and anti-apoptotic responses triggered by ATRA and/
or Lapatinib, as miR over-expression stimulates SKBR3 
cell growth and survival. As for the proliferative action 
of miR-193a-5p and miR-210-3p, this is the result of a 
small, albeit consistent and significant, effect favoring exit 
of SKBR3 cells from the G0/G1-phase of the cell cycle. 
In the case of miR-193a-5p, it is interesting that the miR 
has been reported to inhibit HER2 expression [50]. Thus 
down-regulation of miR-193a-5p by ATRA is against 
an involvement in the inhibitory effect exerted by the 
retinoid on HER2 expression in SKBR3 cells [1]. The data 
on cell motility indicate that the action of miR-125a-5p, 
miR-193a-5p and miR-210-3p needs to be coordinated to 
obtain a pro-motility response. All this demonstrates that 
Module-2 miRs play a role in the control of SKBR3 cell 
cycle and motility, which is in accordance with our process 
enrichment analysis indicating involvement of miR target-
mRNAs in EMT and regulation of growth factors involved 
in G1- to S-phase transition (see Table 2).
Module-3 contains miRs which are predominantly 
up-regulated by ATRA and ATRA+Lapatinib. 
Up-regulation of miR-21, miR-22, miR-103, mir-141 and 
miR-200c supports the anti-oncogenic properties of these 
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regulatory RNAs (Suppl. Table S5). Specifically, miR-22 
induces senescence [71] and inhibits invasiveness [72] 
of breast cancer cells. MiR-103 inhibits mammary tumor 
stem-cell growth [67]. Mir-141 and miR-200c belong to 
the same family of miRs and they inhibit the process of 
EMT in breast cancer cells [20, 73]. Although miR-21 
is generally considered to be oncogenic, we recently 
demonstrated that it is induced by ATRA in estrogen-
receptor-positive mammary tumor cells. In this cellular 
context, miR-21 counteracts the growth-inhibitory 
action, while it contributes to the anti-motility effects 
of ATRA [27]. As for the potential anti-oncogenic miRs 
belonging to Module-3, we focused our attention on miR-
575 and miR-1225-5p, determining the functional activity 
of these miRs in SKBR3 cells. Similar to what is observed 
in the case of the two miRs belonging to Module-1, both 
miR-575 and miR-1225-5p exert an anti-proliferative 
action which involves effects on the cell-cycle. The two 
miRs also inhibit SKBR3 cell random-motility, which is 
supportive of an anti-metastatic action. Thus, miR-575 and 
miR-1225-5p may represent bona fide onco-suppressors in 
Her2+ breast cancer [74, 75].
The expression pattern of the five miRs (miR-148a; 
miR-193a-3p; miR-205; miR-375; miR-660) present 
in Module-4 is complicated, as the overall effect of the 
ATRA+Lapatinib combination is the result of an opposite 
regulatory action exerted by ATRA and Lapatinib alone. 
For this reason, no functional studies were performed with 
any of the Module-4 miRs. Given the complex expression 
pattern of miR-205, miR-375, miR-660, miR-193a-3p 
and miR-148a, it is difficult to discuss the relevance of 
the single members of this module for the growth and 
progression of breast cancer. Nevertheless, high levels 
of miR-375 are present in luminal mammary tumors 
and the miR seems to inhibit EMT [76]. Thus overall 
down-regulation of miR-375 by ATRA+Lapatinib may 
be detrimental for the anti-metastatic activity of this drug 
combination. In addition, pathway enrichment analysis 
indicates that the genes regulated by Module-4 miRs 
control two specific aspects of cancer cell biology, which 
are predominantly related to motility and invasiveness.
Identification of these four sets of miRs is of 
more general interest for breast cancer biology and 
their relevance goes beyond the involvement in ATRA 
and/or Lapatinib anti-tumor action. The Whole miR 
fingerprint defined by all the miRs contained in Module-1 
to Module-4 is associated with the progression of 
breast carcinoma independently of their HER2 status, 
as indicated by studies comparing the miR expression 
profiles in a small cohort of cases consisting of normal 
mammary gland tissue and matched DCIS, IDC and MET 
samples. In fact, two calculated similarity scores based on 
all miRs (General Score) and the subset of over-connected 
miRs (Impact Score) are higher in normal mammary 
tissue than in patient-matched DCIS, IDC and MET. This 
indicates that treatment of the neoplastic SKBR3 cells 
with ATRA and/or Lapatinib changes the miR expression 
profile, making it more similar to that observed in normal 
mammary gland cells. The General Score and the Impact 
Score calculated for Module-1, Module-2 and, to a lesser 
extent, Module-3, separately, also show a trend towards 
a decrease in similarity score with disease progression. 
These observations are consistent with up-regulation of 
Module-1 and Module-3 and down-regulation of Module-2 
miRs by an effective anti-proliferative, cyto-differentiating 
and apoptotic combination of drugs. The data showing 
an association between our overall miR fingerprint are 
supported by the Impact Scores calculated in the much 
larger TCGA dataset of breast cancer samples. In this 
dataset the highest similarity scores are observed in cases 
characterized by a low staging and size index, and there 
is a progressive diminution in the scores as staging and 
size increase. The same associations are determined if the 
fingerprint of over-connected miRs belonging to Module-2 
only is considered. Interestingly, the majority of genes 
whose expression is controlled by Module-2 miRs are 
involved in the regulation of G1- to S-phase progression 
and EMT. Thus, it is relevant that the Module-2 Impact 
Score is inversely correlated with the proliferation score 
of the TCGA tumor samples. Regulation of EMT is of 
particular significance for the inverse association with 
breast cancer progression, as the process is crucial for 
the homeostasis of cancer stem-cells and the invasive/
metastatic behavior of neoplastic cells [36, 77]. Taken 
together the results obtained indicate that the overall miR 
fingerprint and the smaller Module-2 fingerprint have 
diagnostic and prognostic potential.
Given the proposed pro-oncogenic properties and 
the particular relevance of Module-2 miRs for the growth 
and progression of breast cancer which is suggested by the 
associations observed in the clinical dataset, we focused 
our attention on this specific module. We investigated 
whether the regulation of miR-125a-5p, miR-193a-5p 
and miR-210-3p by ATRA, Lapatinib and Doxo as well 
as their activity on growth, survival and motility is limited 
to SKBR3 cells or extends to other cellular models 
representative of breast cancer heterogeneity. For these 
studies, we selected four cell lines [78] characterized by 
distinct phenotypes and different responsiveness to ATRA 
and Lapatinib. In general, the expression results are 
consistent with the idea that the three miRs are endowed 
with pro-oncogenic properties in Her2+ (SKBR3; MDA-
MB453), Basal/TN (MDA-MB157; MDA-MB231) and 
Luminal/ER+ (MCF-7) breast cancer cells. In fact, the 
three miRs are down-regulated by Doxo in almost all 
the cell lines tested and by ATRA or Lapatinib in the 
counterparts sensitive to the anti-proliferative action of 
the two compounds.
The general oncogenic properties of Module-2 miRs 
are confirmed by the effects of miR-125a-5p, miR-193a-5p 
and miR-210-3p over-expression on the growth of MDA-
MB157, MDA-MB231 and MDA-MB453 which are largely 
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in line with what is observed in SKBR3 cells. The only 
exception is represented by MCF-7 cells which show 
complex cell-cycle responses. In fact, the expansion of the 
G0/G1 phase or the contraction of the S phase observed 
upon miR-125a-5p, miR-193a-5p and miR-210-3p 
over-expression suggests a growth inhibitory action, 
although this is not accompanied by the expected effects 
on the G2/M phase. Interestingly, this is consistent with 
the function of miR-125a as an oncosupressor suggested 
by Guo et al. [43] in the MCF-7 model. The results need to 
be confirmed in other Luminal/ER+ and retinoid-sensitive 
cellular models, but they suggest that these Module-2 miRs 
may be anti-oncogenic in this type of mammary tumor. As 
for cell survival, individual Module-2 miRs seem to be 
devoid of significant apoptotic or anti-apoptotic activity 
in the cell lines considered. However, simultaneous over-
expression of miR-125a-5p, miR-193a-5p and miR-210-3p 
reduces caspase-3/7 in MCF-7 and MDA-MB231 cells, 
similar to what is observed in the SKBR3 model. In the 
case of cell motility, the effects of the three Module-2 
miRs are variable and highly dependent on the cellular 
context, preventing us to draw any general conclusion.
A final result of our study is the identification of 
HIPK2 as a novel target of miR-193a-5p and miR-210-3p 
(Module-2). In fact, over-expression of the two individual 
miRs in SKBR3 cells results in down-regulation of 
HIPK2 mRNA and/or protein. Thus, miR-193a-5p and 
miR-210-3p are likely to contribute to the up-regulation 
of HIPK2 by ATRA and ATRA+Lapatinib in SKBR3 cells. 
Up-regulation of HIPK2 in our model is consistent with the 
anti-oncogenic properties of this homeodomain-interacting 
serine/threonine protein kinase [44, 46, 79]. The kinase 
has been reported to promote an apoptotic response and 
to be a mediator of UV-dependent cytotoxicity [79]. In 
addition, HIPK2 has been shown to inhibit the growth and 
invasiveness of breast cancer cells [44, 46]. PLCXD1 is 
a newly identified target transcript of miR-575 and miR-
1225-5p belonging to Module-3. Down-regulation of the 
protein by ATRA, Lapatinib and the combination in SKBR3 
cells is likely to be, at least partly, the consequence of miR-
575 and miR-1225-5p up-regulation. Down-regulation 
of PLCXD1 in our experimental conditions is consistent 
with the idea that this phospholipase C is endowed with 
oncogenic properties. This is contrary to the results 
reported in the only study available on PLCXD1 which 
showed growth-suppressive effects in melanoma cells [47].
In conclusion, our study demonstrates that 
coordinated regulation of numerous miRs of potential 
diagnostic and prognostic value plays an important role 
in the anti-tumor action of ATRA and Lapatinib in the 
SKBR3 breast carcinoma cell line. Some of these effects 
are of general significance, as they are replicated in other 
breast cancer cell lines representing the heterogeneity of 
this disease and with a common anti-tumor agent like 
Doxo. It remains to be established whether the pro- and 
anti-oncogenic properties of Module-1 to -4 miRs can be 
extended to tumors other than breast cancer. With respect 
to this, it is noticeable that members of the miR-125 family 
and miR-193a-3p/-5p are known to act as both oncogenes 
or anti-oncogenes in different types of carcinomas [80, 81].
MATERIALS AND METHODS
Chemicals and cells
ATRA was from Sigma (St Louis, MI, USA) and 
Lapatinib from LC Laboratories (Woburn, MA, USA). 
SKBR3, MD-MB157, MDA-MB231, MCF-7 and MDA-
MB435 cells (ATCC, American-Type-Culture-Collection) 
were seeded at 3 × 105 cells/cm2, cultured and treated as 
described [1].
Transfections and cell viability/
proliferation assays
Transfections of SKBR3 and other breast cancer cell 
lines (3.5 × 104 cells/cm2) with 30 nM miR mimics (Life 
Technologies, Carlsbad, CA) and 0.01 nM pEGFP-N1 
plasmid (Clontech, Mountain View, CA, USA) were 
performed using Lipofectamine-2000 (Life Technologies). 
A list of the miR-mimics is present in Suppl. Table S6. 
Cell numbers and viability were determined with an 
automated Coulter Counter (BD Biosciences, Milan, 
Italy). Proliferation was also evaluated with the 3-(4, 
5-Dimethyl-2-thiazolyl)-2, 5-diphenyl-2H-tetrazolium 
bromide (MTT) assay [82].
Cell-cycle analysis and single-cell random 
motility assays
Cell-cycle analysis was conducted on miR-mimic 
and pEGFP-N1 co-transfected SKBR3 cells as described 
[83]. Random-motility assays were performed on collagen/
BSA coated culture wells by time-lapse microscopy [27].
Western blots and caspase 3/7 assays
Western blot analyses were performed with anti-
PLCXD1 (Abcam, Cambridge, UK; ab67147), anti-
HIPK2 (Abcam, ab108543) and anti-β-actin (Santa Cruz 
Biotechnology, sc-1615) antibodies. The secondary 
antibodies were cyanine-3 or cyanine-5 conjugated 
anti-IgG antibodies (Ambion). Blots were analyzed 
using an automated fluorescence scanner (Typhoon, 
GE-Healthcare, Pittsburgh, PA, USA). Apoptotic 
assays were performed with Apo-ONE-Homogeneous-
Caspase-3/7 Assay (Promega, Madison, WI, USA).
PCR and miR microarrays
RNA was prepared using the mercury-RNA-
isolation-kit (Exiqon, Copenhagen, Denmark) and it 
was reverse-transcribed with the GeneAmp-RNA-PCR-
Core-Kit (Applied Biosystems). PCR was performed 
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with the 7300 system (Applied Biosystems, software 
version 1.3.1). Mature miR levels were measured with 
Taqman assays (Applied Biosystems). Mature miRs were 
also quantified using the Exiqon-LNA-qPCR system using 
miR-425 as a normalising control. HIPK2 and PLCXD1 
mRNAs were determined with Taqman assays (Applied 
Biosystems) following reverse transcription of RNA with 
the GeneAmp RNA PCR Core Kit (Applied Biosystems). 
A list of the Taqman and Exiqon assays are shown in 
Suppl. Table S6.
Human miR microarrays (Release 16.0, 8 × 60K, 
G4870A) were from Agilent (Santa Clara, CA, USA). 
RNA was prepared from five biological replicate cell 
preparations using the miRNeasy-Mini-Kit (Qiagen, 
Milan Italy). RNA labeling, hybridization and data 
extraction (Feature Extraction software v. 10.5) were 
performed according to Agilent protocols. The results 
of the miR microarray experiments were deposited in 
the ArrayExpress database under the accession number, 
E-MTAB-3097.
Integrated miR/mRNA data analysis
Two active datasets from SKBR3 cells were used 
for the analysis: 1) miRs selected for significant 
changes in expression by one of the factors in the 
described microarray experiments (ATRA, Lapatinib, 
or interaction, 36 h treatment; two-way ANOVA, 
p < 0.01); 2) mRNAs selected in the same way from 
previously obtained microarray data (E-MEXP-3192; 
http://www.ebi.ac.uk/arrayexpress) (48 hours; 
p < 0.001). The MAGIA (MiRNA-And-Genes-
Integrated-Analysis) web-tool (http://gencomp.bio.
unipd.it/magia/start/) [84] was used to predict miR/
target mRNA interactions in these two datasets 
(Suppl. Fig. S2). The steps for the analysis were: 1) 
identification of putative miR/target-mRNA pairs by 
anyone of three prediction algorithms (PITA, miRanda, 
TargetScan, filters set as default); 2) for each of these 
pairs, selection of those showing a significant negative 
correlation between miR and mRNA-expression 
(Spearman correlation < −0.9, q-value <0.05).
Cytoscape [85] was used to analyze the predicted 
interaction networks (Fig. 2C). We performed 
enrichment analysis of the target genes in each Module 




We used two datasets: GSE38867 from the NCBI 
Gene Expression Omnibus (http://www.ncbi.nlm.nih 
.gov/gds) and the Breast Invasive Carcinoma miRNAseq 
and Gene expression (RNA-seq) dataset from the Cancer 
Genome Atlas (TCGA, http://cancergenome.nih.gov). The 
similarity score was defined as follows:
where wi is the weight of i
th miR in signature (+1 for 
miRs in Module-1 and -3; -1 for miRs in Module-2 and -4) 
and xi is the expression value of i
th miR in test samples. We 
calculated two types of similarity scores: a General Score 
based on all the miRs and an Impact Score based on the 
subset of over-connected miRs (miRs with degree >50, 
i.e. those with more than 50 predicted target-mRNAs). 
The scores were analyzed in relation to tumor progression 
stages in the first dataset, and to several parameters in 
the second dataset: normal tissue versus tumor, tumor 
size and stage, tumor proliferation score [86] and overall 
survival. Survival analyses (Kaplan-Meier, rank [87] and 
Cox-proportional-hazard tests) were performed using 
the “survival” package in R Bioconductor (http://www 
.bioconductor.org).
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